ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
Another twist in Cardiff’s onvansertib plan
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
No keeping the red light on for Sting
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
